Absci Corp amendment to a Schedule 13G/A shows The Vanguard Group reports zero shares beneficially owned and 0% of Absci Corp common stock following an internal realignment. The filing clarifies that certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538.
Absci Corporation outlines its AI-native biopharmaceutical strategy and growing pipeline in its annual report, highlighting progress on antibody programs built with its Integrated Drug Creation platform.
Lead candidate ABS-201, an anti-PRLR antibody, is in the HEADLINE™ Phase 1/2a trial for androgenetic alopecia, with early cohorts dosed and interim safety and exploratory efficacy data expected in 2026 and full proof-of-concept in 2027. The same drug is being advanced toward a planned Phase 2 trial in endometriosis in late 2026.
The company describes its Origin‑1 generative AI system for de novo antibody design, a lab-in-the-loop validation engine, and a business model that blends internally developed programs with partnerships. Absci also notes significant ongoing losses, the need for additional capital, heavy reliance on its platform’s technical success, and intense competition in AI-enabled biologic drug discovery.
Absci Corporation reported 2025 results showing a widening loss as it invested heavily in its AI-driven drug pipeline while advancing lead program ABS-201. Revenue was $2.8 million for 2025, down from $4.5 million in 2024, reflecting lower partner program revenue.
Research and development expenses rose to $81.4 million from $63.9 million, driving a full-year net loss of $115.2 million versus $103.1 million a year earlier. Fourth-quarter net loss was $29.6 million. A $5.1 million gain from settling contingent consideration added $8.7 million of unrestricted cash.
The company highlighted clinical progress for ABS-201 in androgenetic alopecia, having dosed the first three cohorts in the Phase 1/2a HEADLINE trial with favorable emerging safety data and human ex vivo hair-growth findings. It also plans a Phase 2 trial of ABS-201 in endometriosis in the fourth quarter of 2026 and continues partnering efforts around ABS-101 and other AI-designed antibodies.
Cash, cash equivalents, and marketable securities totaled $144.3 million as of December 31, 2025, compared with $152.5 million as of September 30, 2025. Absci believes this liquidity will fund operations into the first half of 2028, supporting its multi-program clinical and discovery agenda.
Absci Corp Chief Legal Officer Shelby J. Walker reported compensation-related equity awards and tax withholding transactions. On March 2, 2026, Walker received 90,300 shares of Common Stock in the form of Restricted Stock Units under the 2021 plan, which will vest in three substantially equal annual installments starting on March 1, 2027, subject to continued service. On the same date, Walker was granted a stock option for 356,300 shares of Common Stock at an exercise price of $2.80 per share, also vesting in three substantially equal annual installments beginning on March 1, 2027. On March 3, 2026, 9,825 shares of Common Stock were withheld by Absci to cover tax obligations from RSU vesting, which the filing states was not a discretionary trade. Following these transactions, Walker directly owned 139,775 shares of Common Stock.
Absci Corp CFO/CBO Zachariah Jonasson reported routine equity compensation and related tax withholding. On March 2, 2026, he received awards of 135,400 shares of Common Stock as restricted stock units and stock options for 534,400 shares of Common Stock with a $2.80 exercise price, vesting in three equal annual installments starting March 1, 2027.
On March 3, 2026, 10,848 shares of Common Stock were withheld at $2.80 per share to cover tax obligations from RSU vesting, which the company states was not a discretionary trade. After these transactions, he directly owns 499,783 Common Stock shares and holds 534,400 stock options.
Absci Corp senior vice president and chief accounting officer Todd Bedrick reported routine equity compensation grants and related tax withholding. He received 49,600 shares of common stock as restricted stock units under the 2021 Stock Option and Incentive Plan, which will vest in three equal annual installments starting on March 1, 2027, contingent on continued service.
Bedrick was also granted stock options covering 195,900 shares of common stock at an exercise price of $2.80 per share, expiring on March 1, 2036, vesting in substantially equal annual installments over three years beginning March 1, 2027. In connection with the vesting of restricted stock units, 5,282 shares of common stock were withheld by Absci to cover tax obligations, leaving him with 216,942 common shares held directly; this withholding was not a discretionary market sale.
Absci Corp CEO Sean McClain reported equity compensation grants and related tax withholding. On 2026-03-02, he received 406,200 shares of Common Stock as a restricted stock unit award and a stock option for 1,603,200 shares of Common Stock at an exercise price of $2.80 per share, both vesting in three substantially equal annual installments starting on March 1, 2027, subject to continued service. On 2026-03-03, 25,316 shares of Common Stock were withheld by Absci to cover tax obligations from RSU vesting, which the filing notes was not a discretionary trade. After these transactions, McClain directly held 8,715,451 shares of Common Stock.
Absci Corp’s Chief Innovation Officer buys additional shares. Executive Andreas Busch reported an open-market purchase of 100,000 shares of Absci common stock at a price of $2.29 per share on March 12, 2026, in accordance with the company’s trading policies. This increased his direct ownership to 421,446 shares.
Absci Corporation updated its governance and leadership structure. The board approved amended and restated indemnification agreements for all current directors and officers, adding more detailed change-in-control definitions, a presumption of good faith for officer indemnitees, coverage for separate counsel after a change in control, and an exclusion for incentive- and equity-based compensation subject to Rule 10D-1 clawbacks.
Chief Innovation Officer Andreas Busch, Ph.D. will retire effective March 31, 2026, then serve as a scientific advisor for two years starting April 3, 2026. Under an Advisor Agreement, he will receive a $25,500 annual cash retainer and equity awards of stock options for 22,800 shares and 5,800 restricted stock units. The company extended the exercise period on 2,489,290 vested stock options he holds, generally until three months after his advisory service ends or their original expiration, with specific provisions for cause, death, or disability; all unvested options at retirement will lapse.
Absci also announced the appointment of Ransi Somaratne, M.D., a veteran clinical development leader, as Chief Medical Officer to lead clinical strategy for its AI-designed therapeutics pipeline, including the ABS-201 program.
Pangalos Menelas N reported acquisition or exercise transactions in this Form 4 filing.
Absci Corp director Menelas N. Pangalos reported equity awards tied to his role on the company’s scientific advisory board. He received stock options for 22,800 shares and a grant of 5,800 Restricted Stock Units (RSUs), both at no cash cost per share.
The RSUs are scheduled to vest and settle over one year beginning on January 1, 2026, in substantially equal monthly installments, conditioned on his continuous service. The stock options follow the same one-year, monthly vesting schedule starting on that date. Following the RSU grant, his directly held common stock position is 194,855 shares.